NEW YORK – Precision medicine startup Curesponse has raised $6 million in a Series A financing round with participation from investors including London-based NCL Technology Ventures and Israel-based aMoon.
The Rehovot, Israel-based precision medicine firm will use the funding to scale clinical trials for its cResponse functional cancer testing platform and expansion to the UK.
Curesponse's cResponse platform preserves a patient's tumor in 3D for up to two weeks, allowing users to observe the cancer microenvironment's response to cancer therapies.
Developed by Ravid Straussman, scientific founder of Curesponse and senior scientist at the Weizmann Institute in Rehovot, cResponse offers actionable information for clinicians by indicating the optimal drug selection for each patient.
Curesponse believes the platform may potentially save lives, curb the cost of treatment, and aid research and development clinical trials as a companion diagnostic for pharmaceutical companies.
"The last few years have brought significantly greater attention to the importance of personalized medicine in patient care in the UK," Guy Neev, CEO of Curesponse, said in a statement. "We are collaborating with leading clinical sites in London and throughout England to make this technology available to patients as quickly as possible."